Figure 4
Figure 4. OS in 200 patients with relapse during or after chemotherapy, no Ph+ ALL, and no CNS involvement and for whom data on salvage therapy and SCT were available. (A) OS according to performance of SCT: SCT, n = 149 (solid line), 38% ± 4% after 3 years, median 14.7 months; no SCT, n = 51 (dashed line), 0% after 1 year, median 2.7 months (P < .0001). (B) OS according to SCT timing: SCT in CR after first salvage, n = 65 (solid line), 56% ± 7% after 3 years, median not reached; SCT in later CR, n = 21 (short dashed line), 39% ± 11% after 3 years, median 14.8 months; and SCT without CR, n = 63 (long dashed line), 20% ± 5% after 3 years, median 9 months (P < .0001).

OS in 200 patients with relapse during or after chemotherapy, no Ph+ ALL, and no CNS involvement and for whom data on salvage therapy and SCT were available. (A) OS according to performance of SCT: SCT, n = 149 (solid line), 38% ± 4% after 3 years, median 14.7 months; no SCT, n = 51 (dashed line), 0% after 1 year, median 2.7 months (P < .0001). (B) OS according to SCT timing: SCT in CR after first salvage, n = 65 (solid line), 56% ± 7% after 3 years, median not reached; SCT in later CR, n = 21 (short dashed line), 39% ± 11% after 3 years, median 14.8 months; and SCT without CR, n = 63 (long dashed line), 20% ± 5% after 3 years, median 9 months (P < .0001).

Close Modal

or Create an Account

Close Modal
Close Modal